Matched Placebo (Capsules)

Preclinical

Matched Placebo (Capsules) is one of 9 therapeutic programs targeting Osteoporosis (Senile). It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Osteoporosis (senile)Completed

BoneCompleted

Osteoporosis (senile)Preclinical

Completed

BonePreclinical

Completed

Competition

Competitive Landscape

12 competitors in Bone

#DrugCompanyPhaseTrials

Invanz

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 2

BOOST Cells

KKarolinska Institutet

Phase 2

1 3

Bone Marrow Aspirate Concentrate

MMassachusetts General Hospital

Preclinical

2 4

Platelet-Rich Fibrin (PRF)

FFederal University of São Paulo

Preclinical

1 5

Matched Placebo (Capsules)

CCreighton University

Preclinical

3 6

Vertebral Bone Marrow Clot

IIstituto Ortopedico Rizzoli

Preclinical

1 7

Bmmncs

CChaitanya Hospital, Pune

Preclinical

1 8

Puregen Osteoprogenitor Cell Allograft

AAlphatec Spine, Inc.

Preclinical

1 9

Elelyso

SShaare Zedek Medical Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

PreclinicalNot yet recruiting

Alzheimer's Disease

NCT07459959

Q4 2030

Phase 2Not yet recruiting

Clonal Cytopenia of Uncertain Significance

NCT07435636

Clinical

Trials by Indication[1]

Clonal Cytopenia of Uncertain Significance1 trial

A Multi-centre, Double-blind, Placebo-controlled Randomised Phase II Trial to Evaluate the Effect of Low Dose Decitabine and Tetrahydrouridine in Individuals With High-risk Clonal Haematopoiesis

Not yet recruiting·CClinical Hub for Interventional Research (CHOIR)·Phase 2·NCT07435636·80 enrolled

Alzheimer's Disease1 trial

LiO-AD: Lithium Orotate in Alzheimers Disease Feasibility, Biomarker Engagement, and Clinical Response

Not yet recruiting·JJohns Hopkins University·Preclinical·NCT07459959·40 enrolled

Osteoporosis (Senile)1 trial

Efficacy and Safety of Doxercalciferol on Spinal and Femoral Density in Postmenopausal Osteopenic Women

Completed·CCreighton University·Preclinical·NCT07660536·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Matched Placebo (Capsules). U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Matched Placebo (Capsules). EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Creighton University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: CCreighton University

Matched Placebo (Capsules)

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2029

Q4 2030

Trials by Indication[1]

Clonal Cytopenia of Uncertain Significance1 trial

Alzheimer's Disease1 trial

Osteoporosis (Senile)1 trial

References

Drug Info

Quick Facts

Related News